Dr. Mukherjee is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.
Cancers Treated:
Research Interests:
Use of immune checkpoint inhibitors in solid tumorsAbout Sarbajit Mukherjee
Biography:
I am a gastrointestinal medical oncologist with a research focus on novel clinical trials and cancer immunotherapy. I have gained experience in translational research and clinical trial design through a Master's program in clinical and translational science. My current work involves understanding the biology of gastrointestinal cancers and designing novel clinical trials to improve patient outcomes. Besides, I am interested in studying mechanisms of immune dysfunction in obese cancer patients and the use of immune checkpoint inhibitors in solid tumors. I have led over a dozen clinical trials as a Principal Investigator (PI) and received six grants as a PI or co-investigator. Many of my studies are investigator-initiated and grant-funded through national organizations like the National Cancer Institute (NCI) and the department of defense (DOD). My work has resulted in several national/international presentations and peer-reviewed publications in high-impact journals. As a physician-scientist, my goal is to conduct innovative clinical trials using novel immunotherapy agents and take discoveries from the lab to the bedside to improve life expectancy as well as the quality of life of cancer patients. As an educator, I strive to improve the quality of oncology education and mentor the next generation of clinician investigators.
I have had the opportunity to serve the American Society of Clinical Oncology (ASCO). I have been a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee, and the Professional Development Committee at ASCO. I have also served on multiple guidelines panels for ASCO. Currently, I am a guidelines panel member at the National Comprehensive Cancer Network and at the International Society for Diseases of the Esophagus.
I have been fortunate to receive many national and international awards. I have been asked to review manuscripts for reputed journals and grant applications for federal funding agencies.
For me, caring for a cancer patient is more than treating a disease; it's a healing process involving both the patient's body, mind, and caregivers. I would like to see myself as a successful clinical and translational researcher and a compassionate physician, and a thought leader in the field of gastrointestinal cancers.
Positions
- Assistant Professor of Oncology
- Assistant Professor of Immunology
- Department of Medicine
- Co-Leader, GI Translational Research Group
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
- Assistant Professor
Background
Education and Training:
- 2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
- 2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK
Residency:
- 2012-2015 - Saint Joseph Hospital, Chicago, IL
Fellowship:
- 2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK
Board Certification:
- 2018 - Medical Oncology - American Board of Internal Medicine
- 2018 - Hematology - American Board of Internal Medicine
- 2015 - Internal Medicine - American Board of Internal Medicine
Professional Memberships:
- Society for Immunotherapy of Cancer
- American Association for Cancer Research
- American College of Gastroenterology
- North American Neuroendocrine Tumor Society
- European Society of Medical Oncology
- American Society of Clinical Oncology
Professional Experience:
- 2021-present - Quality Subcommittee, Society for Immunotherapy of Cancer (SITC)
- 2018-present - Board of Directors, Esophageal Cancer Action Network
- 2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
- 2017-2018 - Clinical Practice Guidelines Committee, ASCO
- 2016-2018 - Professional Development Committee, ASCO
Honors & Awards:
- Clinical Investigator Scholarship Award, North American Neuroendocrine Tumor Society
- ASCO/AACR Methods in Clinical Cancer Workshop, Vail, CO
- James N. George award for the outstanding fellow in hematology-oncology, University of Oklahoma
- Gold Humanism Honor Society
- Conquer Cancer Foundation Merit Award, ASCO
- Alpha Omega Alpha (AOA) Honor Medical Society
- Early Career Reviewer, Developmental Therapeutics (DT), Center for Scientific Review, National Institutes of Health
- Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop participant
- Young Investigator Award, ESMO World Congress on Gastrointestinal Cancer
Clinical Trials
Featured on Cancer Talk
Showing all3 of 5 CollapseView all
Publications
1. Parmar K, Subramanyam S, Attwood K, Appiah D, Fountzilas C, Mukherjee S. Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Pharmaceutics. 2022;14(9):1953. PMID: 36145703.
2. Deng L, Groman A, Jiang C, Perimbeti S, Gabriel E, Kukar M, Mukherjee S. Association of Preoperative Chemosensitivity With Postoperative Survival in Patients With Resected Gastric Adenocarcinoma. JAMA Netw Open. 2021 Nov 1;4(11): e2135340. PMID: 34797369
3.Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel). 2021 Apr 7;13(8):1753. doi: 10.3390/cancers13081753. PMID: 33916960; PMCID: PMC8067543.
4. Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer. 2020 Feb 15;126(4):792-799. PubMed PMID: 31714595.
5.Mukherjee S, Fountzilas C, Boland PM, Gosain R, Attwood K, Tan W, Khushalani N, Iyer R. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Target Oncol. 2019 Dec 4. PubMed PMID: 31802410.